Evidence map›Paper›PMID 32543699›Full record

ArticleJAMA network open2020

Estimated Prevalence of Asthma in US Children With Developmental Disabilities.

Luyu Xie, Andrew Gelfand, George L Delclos, Folefac D Atem, Harold W Kohl, Sarah E Messiah

Abstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Paediatric asthma and non-allergic comorbidities: A review of current risk and proposed mechanisms.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luyu XieSchool of Public Health, University of Texas Health Science Center at Houston, Dallas Campus, Dallas.
Andrew GelfandDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas.
George L DelclosSchool of Public Health, University of Texas Health Science Center at Houston, Houston campus, Houston.
Folefac D AtemSchool of Public Health, University of Texas Health Science Center at Houston, Dallas Campus, Dallas.
Harold W KohlSchool of Public Health, University of Texas Health Science Center at Houston, Austin campus, Austin.
Sarah E MessiahSchool of Public Health, University of Texas Health Science Center at Houston, Dallas Campus, Dallas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: The prevalence of asthma in US children with various developmental disabilities and delays is unclear, including how estimates vary by ethnic group. Objective: To report asthma prevalence estimates by various disability categories and developmental delays in a diverse sample of the US pediatric population. Design, Setting, and Participants: This population-based cross-sectional study encompassed a total of 71 811 families with children or adolescents aged 0 to 17 years (hereinafter referred to as children) who participated in the 2016 and 2017 National Survey of Children's Health. Data were collected from June 10, 2016, to February 10, 2017, for the 2016 survey and from August 10, 2017, to February 10, 2018, for the 2017 survey. Data were analyzed from September 20, 2019, to April 5, 2020. Exposures: Developmental disability, including attention-deficit/hyperactivity disorder, autism spectrum disorder, cerebral palsy, seizure, intellectual and/or learning disability, and vision, hearing, and/or speech delay. Delay was defined as not meeting growth milestones with unknown cause. Main Outcomes and Measures: Weighted asthma prevalence estimates and 95% CIs were generated for children with and without disabilities. Results: A total of 71 811 participants (mean [SE] age, 8.6 [0.1] years; 36 800 boys [51.1%; 95% CI, 50.2%-52.0%]; 50 219 non-Hispanic white [51.4%; 95% CI, 50.6%-52.3%]) were included in our final analytical sample, of whom 5687 (7.9%; 95% CI, 7.5%-8.4%) had asthma and 11 426 (15.3%; 95% CI, 14.7%-16.0%) had at least 1 disability. Overall asthma prevalence estimates were 10 percentage points higher in children with a disability (16.1%; 95% CI, 14.3%-17.8%) vs children without a disability (6.5%; 95% CI, 6.0%-6.9%). The odds of asthma were significantly higher in children with a disability (odds ratio [OR], 2.77; 95% CI, 2.39-3.21) or delay (OR, 2.22; 95% CI, 1.78-2.77) vs typically growing children. Adjusted models remained significant for all disability categories (overall adjusted OR, 2.21; 95% CI, 1.87-2.62). Subgroup analyses showed ethnic minorities had a higher prevalence of concurrent asthma and developmental disabilities vs non-Hispanic whites (19.8% [95% CI, 16.6%-23.0%] vs 12.6% [95% CI, 11.1%-14.0%]; P < .001). Conclusions and Relevance: These results suggest that US children with various developmental disabilities or delay may have higher odds for developing asthma vs their typically developing peers. These findings support asthma screening in pediatric health care settings among patients with developmental disabilities and delays, particularly among those from ethnic minority backgrounds. In addition, very young children with asthma should be screened for disabilities and delays, because temporality cannot be determined by the current data source and analytical approach.

Indexed as

AdolescentAsthmaChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMaleNeurodevelopmental DisordersPrevalenceUnited States

Identifiers

PMID32543699
PMCPMC7298611

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.